Oxford Biomedica is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Working across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, we provide innovative solutions to meet our partner’s process development, analytical development, and manufacturing needs. Making us the ideal cell and gene therapy vector partner.

OXB Solutions, our US based best-in-class AAV manufacturing and innovation business is raising the bar in AAV development and manufacturing solutions. Offering full scope process development and GMP operations using a commercially ready ‘plug and play’ platform. The execution and data speak for itself:

  • HEK293 suspension process scaled up from 2L to 2000L
  • Dual plasmid system with optimised transfection demonstrating E15 vg/L in bioreactors
  • Demonstrated >90% fully intact vector
  • Analytical toolbox with 40+ methods developed and qualified in-house
  • Delivered greater than 45 500L GMP batches in the last three years
  • 6 successful IND regulatory filings

Our well-established and industry leading lentiviral vector platform, LentiVector® platform, is used to develop product candidates in-house, before seeking partners to take the products into clinical trials. Our platform, IP, patents, and know-how, along with our 25 plus years of expertise in applying its lentiviral vector technology, has taken us from pioneers in the field to the sector leader we are today.

Leveraging our state-of-the-art manufacturing facilities and purpose-built laboratories, we help our partners achieve successful commercialisation of their viral vector-based products.

Based in Oxfordshire, UK and greater Boston, US, we employ more than 940 people. We drive credible science and innovation to help our partners realise incredible results. Discover how at www.oxb.com or email partnering@oxb.com for lentivirus and adenovirus information, or solutions.partnering@oxb.com for AAV.